Literature DB >> 6777920

Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa.

D A Mitchison, A B Keyes, E A Edwards, P Ayuma, S P Byfield, A J Nunn.   

Abstract

During intensive bacteriological follow-up of 2123 patients who had received short course chemotherapy regimens in 4 controlled clinical trials in Africa and had not had a bacteriological relapse, 405 isolated positive cultures were obtained from 37 429 sputum specimens in 3 East African laboratories. These cultures might have arisen as a result of clerical error, of transfer of bacilli from positive to negative specimens in the laboratory or from the lesions of the patients. Clerical error in the labelling of specimens or the recording of results did not seem a frequent cause, since isolated positive cultures contained many fewer colonies than cultures from other positive specimens being processed at the same time. Several of evidence suggested that some isolated positive cultures arose from the lesions of patients: a decrease in their incidence occurred in successive time periods after chemotherapy; the number of isolated positives per patient departed significantly from the Poisson distribution; they were more often drug resistant than other cultures processed at the time; positive cultures were obtained less frequently from known autoclaved specimens inserted among the the study specimens than from the study specimens themselves; no association was found between the incidence of isolated positive and of specimens containing numerous viable M. tuberculosis being processed at the same time. Nevertheless some of these cultures probably arose by transfer in the laboratory, since the rates at which transfer were known to occur differed in the 3 laboratories and corresponded to the rates of obtaining isolated positive cultures.

Entities:  

Mesh:

Year:  1980        PMID: 6777920     DOI: 10.1016/0041-3879(80)90002-1

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  10 in total

1.  Estimation of the rate of unrecognized cross-contamination with mycobacterium tuberculosis in London microbiology laboratories.

Authors:  M Ruddy; T D McHugh; J W Dale; D Banerjee; H Maguire; P Wilson; F Drobniewski; P Butcher; S H Gillespie
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Specimen contamination in mycobacteriology laboratory detected by pseudo-outbreak of multidrug-resistant tuberculosis: analysis by routine epidemiology and confirmation by molecular technique.

Authors:  R Wurtz; P Demarais; W Trainor; J McAuley; F Kocka; L Mosher; S Dietrich
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

3.  Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures.

Authors:  P M Small; N B McClenny; S P Singh; G K Schoolnik; L S Tompkins; P A Mickelsen
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

4.  Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Authors:  J Furin; E Alirol; E Allen; K Fielding; C Merle; I Abubakar; J Andersen; G Davies; K Dheda; A Diacon; K E Dooley; G Dravnice; K Eisenach; D Everitt; D Ferstenberg; A Goolam-Mahomed; M P Grobusch; R Gupta; E Harausz; M Harrington; C R Horsburgh; C Lienhardt; D McNeeley; C D Mitnick; S Nachman; P Nahid; A J Nunn; P Phillips; C Rodriguez; S Shah; C Wells; B Thomas-Nyang'wa; P du Cros
Journal:  Int J Tuberc Lung Dis       Date:  2016-03       Impact factor: 2.373

5.  A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project.

Authors:  Corinne S C Merle; Charalambos Sismanidis; Oumou Bah Sow; Martin Gninafon; John Horton; Olivier Lapujade; Mame Bocar Lo; Denis A Mitchinson; Christian Perronne; Francoise Portaels; Joseph Odhiambo; Piero Olliaro; Roxana Rustomjee; Christian Lienhardt; Katherine Fielding
Journal:  Trials       Date:  2012-05-18       Impact factor: 2.279

6.  A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.

Authors:  Patrick P J Phillips; Carl M Mendel; Andrew J Nunn; Timothy D McHugh; Angela M Crook; Robert Hunt; Anna Bateson; Stephen H Gillespie
Journal:  BMC Med       Date:  2017-11-24       Impact factor: 8.775

7.  Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.

Authors:  Ray Y Chen; Laura E Via; Lori E Dodd; Gerhard Walzl; Stephanus T Malherbe; André G Loxton; Rodney Dawson; Robert J Wilkinson; Friedrich Thienemann; Michele Tameris; Mark Hatherill; Andreas H Diacon; Xin Liu; Jin Xing; Xiaowei Jin; Zhenya Ma; Shouguo Pan; Guolong Zhang; Qian Gao; Qi Jiang; Hong Zhu; Lili Liang; Hongfei Duan; Taeksun Song; David Alland; Michael Tartakovsky; Alex Rosenthal; Christopher Whalen; Michael Duvenhage; Ying Cai; Lisa C Goldfeder; Kriti Arora; Bronwyn Smith; Jill Winter; Clifton E Barry Iii
Journal:  Gates Open Res       Date:  2017-11-06

8.  Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.

Authors:  Josephine M Bryant; Simon R Harris; Julian Parkhill; Rodney Dawson; Andreas H Diacon; Paul van Helden; Alex Pym; Aziah A Mahayiddin; Charoen Chuchottaworn; Ian M Sanne; Cheryl Louw; Martin J Boeree; Michael Hoelscher; Timothy D McHugh; Anna L C Bateson; Robert D Hunt; Solomon Mwaigwisya; Laura Wright; Stephen H Gillespie; Stephen D Bentley
Journal:  Lancet Respir Med       Date:  2013-11-21       Impact factor: 30.700

9.  Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial.

Authors:  P P J Phillips; A Van Deun; S Ahmed; R L Goodall; S K Meredith; F Conradie; C-Y Chiang; I D Rusen; A J Nunn
Journal:  BMC Med       Date:  2020-11-04       Impact factor: 8.775

10.  Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

Authors:  Andrew J Nunn; I D Rusen; Armand Van Deun; Gabriela Torrea; Patrick P J Phillips; Chen-Yuan Chiang; S Bertel Squire; Jason Madan; Sarah K Meredith
Journal:  Trials       Date:  2014-09-09       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.